TAMPA, Fla., May 14, 2024 /PRNewswire/ -- Valcare Medical,
Inc., a leading innovator in transcatheter-based mitral solutions,
announces the successful completion of the first two enrollments in
the AMEND TS European pilot study. Dr. Bruno Melica and the
team from Vila Nova de Gaia Hospital, Portugal, performed the procedures.
The purpose of the study is to build upon the positive results
from the first in human experience in which 33 patients were
successfully treated with the AMEND Trans-Septal System. The
AMEND TS EU Pilot Study will evaluate the safety and performance of
the AMEND Trans-Septal System as the primary technique in a
comprehensive mitral repair approach comprising mitral annuloplasty
as a standalone therapy or in combination with additional approved
technologies to achieve a surgical-level repair.
The innovative AMEND mitral valve repair device is a closed,
D-shaped semi-rigid annuloplasty ring with proprietary anchoring
capabilities. AMEND is designed to replicate the efficacy of the
traditional annuloplasty rings used to treat mitral regurgitation
during open-heart surgery, but is implanted via a less invasive,
percutaneous approach.
"We are thrilled to have successfully implanted the AMEND
annuloplasty ring in the initial two patients enrolled in the AMEND
TS EU pilot study," commented Dr. Bruno Melica, Interventional
Cardiologist at Vila Nova de Gaia Hospital, Portugal. "These procedures mark a significant
advancement in addressing an unmet need for patients at high risk
for mitral valve surgery."
"The enrollment of the first two patients in the AMEND EU Pilot
Study marks an important milestone in Valcare's mission to provide
a surgical-style result for high-risk patients suffering from
severe functional mitral regurgitation," said Steve Sandweg, CEO, Valcare Medical, Inc. "We
are grateful to Dr. Melica and his team for their incredible
support and collaboration during this study and look forward to
continuing this important journey together."
The AMEND TS EU Pilot Study will enroll a total of 20 patients
in several European sites and follow each patient for a period of
12 months. Following completion of the EU pilot study,
Valcare plans to continue working with the FDA on a future IDE
submission.
The AMEND device is investigational and limited to
investigational use only. The products are not available for sale
or commercial distribution.
About Valcare Medical:
Valcare Medical is dedicated to providing innovative minimally
invasive technologies for the treatment of mitral
regurgitation.
For media inquiries, please
contact:
info@valcaremedical.com
www.valcaremedical.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/valcare-medical-announces-enrollment-of-first-two-patients-in-amend-ts-eu-pilot-study-302143860.html
SOURCE Valcare Medical